Aromatase and regulating the estrogen: Androgen ratio in the prostate gland

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 4-5, 2010, Pages 246-251

  Ellem, Stuart J ^a   Risbridger, Gail P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Aromatase; Estrogen; Prostate; Prostate cancer

Indexed keywords

AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; TESTOSTERONE; ANDROGEN; ESTROGEN; ESTROGEN RECEPTOR;

ADULTHOOD; CARCINOGENESIS; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; HOMEOSTASIS; HORMONE ACTION; HUMAN; INFLAMMATION; MALE; PROSTATE; PROSTATE CANCER; PROSTATE DISEASE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STROMA; TESTOSTERONE BLOOD LEVEL; ENZYMOLOGY; METABOLISM; PROSTATE TUMOR; REVIEW;

ANDROGENS; AROMATASE; ESTROGENS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 77950363332     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.10.015     Document Type: Conference Paper

References (92)

1. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002, CA Cancer J. Clin. 55 (2) (2005) 74-108.
2. C. Huggins, C.V. Hodges, Studies on prostatic cancer. The effect of castration, of estrogen and of androgen interaction on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res. 1 (1941) 293-297.
3. C. Huggins, Endocrine-induced regression of cancers, Cancer Res. 27 (11) (1967) 1925-1930.
4. A. Brodie, Q. Lu, J. Nakamura, Aromatase in the normal breast and breast cancer, J. Steroid Biochem. Mol. Biol. 61 (3-6) (1997) 281-286.
5. S. Chen, Aromatase and breast cancer, Front. Biosci. 3 (1998) d922-d933.
6. N. Harada, Aberrant expression of aromatase in breast cancer tissues, J. Steroid Biochem. Mol. Biol. 61 (3-6) (1997) 175-184.
7. H. Sasano, H. Nagura, N. Harada, Y. Goukon, M. Kimura, Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders, Hum. Pathol. 25 (5) (1994) 530-535.
8. H. Sasano, M. Ozaki, Aromatase expression and its localization in human breast cancer, J. Steroid Biochem. Mol. Biol. 61 (3-6) (1997) 293-298.
9. E.R. Simpson, T. Price, J. Aitken, M. Mahendroo, G. Means, M. Kilgore, The aromatase enzyme: from cloning to cancer, Princess Takamatsu Symp. 21 (1990) 75-87.
10. P. Sourdaine, P. Mullen, R. White, J. Telford, M.G. Parker, W.R. Miller, Aromatase activity and CYP19 gene expression in breast cancers, J. Steroid Biochem. Mol. Biol. 59 (2) (1996) 191-198.
11. S.E. Bulun, K. Economos, D. Miller, E.R. Simpson, CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors, J. Clin. Endocrinol. Metab. 79 (6) (1994) 1831-1834.
12. K. Watanabe, H. Sasano, N. Harada, M. Ozaki, H. Niikura, S. Sato, A. Yajima, Aromatase in human endometrial carcinoma and hyperplasia. immunohistochemical, in situ hybridization, and biochemical studies, Am. J. Pathol. 146 (2) (1995) 491-500.
13. A. Vermeulen, R. Rubens, L. Verdonck, Testosterone secretion and metabolism in male senescence, J. Clin. Endocrinol. Metab. 34 (4) (1972) 730-735.
14. J.L. Tenover, Testosterone replacement therapy in older adult men, Int. J. Androl. 22 (5) (1999) 300-306.
15. A. Vermeulen, J.M. Kaufman, S. Goemaere, I. van Pottelberg, Estradiol in elderly men, Aging Male 5 (2) (2002) 98-102.
16. E.E. Baulieu, Androgens and aging men, Mol. Cell Endocrinol. 198 (1-2) (2002) 41-49.
17. A. Gray, J.A. Berlin, J.B. McKinlay, C. Longcope, An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis, J. Clin. Epidemiol. 44 (7) (1991) 671-684.
18. A. Gray, H.A. Feldman, J.B. McKinlay, C. Longcope, Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study, J. Clin. Endocrinol. Metab. 73 (5) (1991) 1016-1025.
19. Z. Culig, A. Hobisch, M.V. Cronauer, A.C. Cato, A. Hittmair, C. Radmayr, J. Eberle, G. Bartsch, H. Klocker, Mutant androgen receptor detected in an advancedstage prostatic carcinoma is activated by adrenal androgens and progesterone, Mol. Endocrinol. 7 (12) (1993) 1541-1550.
20. S. McPherson, H. Wang, M. Jones, J. Pedersen, T. Iismaa, N. Wreford, E. Simpson, G. Risbridger, Elevated androgens and prolactin in aromatase deficient (ArKO) mice cause enlargement but not malignancy of the prostate gland, Endocrinology 142 (6) (2001) 2458-2467.
21. R.L. Noble, Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen, Cancer Res. 40 (10) (1980) 3547-3550.
22. I. Leav, S.M. Ho, P. Ofner, F.B. Merk, P.W. Kwan, D. Damassa, Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats, J. Natl. Cancer Inst. 80 (13) (1988) 1045-1053.
23. M.C. Bosland, The role of steroid hormones in prostate carcinogenesis, J. Natl. Cancer Inst. Monogr. (27) (2000) 39-66.
24. Y. Wang, S.W. Hayward, A.A. Donjacour, P. Young, T. Jacks, J. Sage, R. Dahiya, R.D. Cardiff, M.L. Day, G.R. Cunha, Sex hormone-induced carcinogenesis in Rbdeficient prostate tissue, Cancer Res. 60 (21) (2000) 6008-6017.
25. W.A. Ricke, Y. Wang, G.R. Cunha, Steroid hormones and carcinogenesis of the prostate: the role of estrogens, Differentiation 75 (9) (2007) 871-882.
26. P. Hill, L. Garbaczewski, A.R. Walker, Age, environmental factors and prostatic cancer, Med. Hypotheses 14 (1) (1984) 29-39.
27. R. Ross, L. Bernstein, H. Judd, R. Hanisch, M. Pike, B. Henderson, Serum testosterone levels in healthy young black and white men, J. Natl. Cancer Inst. 76 (1) (1986) 45-48.
28. B.E. Henderson, L. Bernstein, R.K. Ross, R.H. Depue, H.L. Judd, The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring, Br. J. Cancer 57 (2) (1988) 216-218.
29. F.H. de Jong, K. Oishi, R.B. Hayes, J.F. Bogdanowicz, J.W. Raatgever, P.J. van der Maas, O. Yoshida, F.H. Schroeder, Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study, Cancer Res. 51 (13) (1991) 3445-3450.
30. W.E. Farnsworth, Roles of estrogen and SHBG in prostate physiology, Prostate 28 (1) (1996) 17-23.
31. T.P. Page, D.L. Lin, D.L. Hess, J.K. Amory, P.S. Nelson, A.M. Matsumoto, W.J. Bremner, Prostate tissue dihydrotestosterone, but not testosterone, levels are decreased by medical castrationin normal, middle-aged men, in: The 87th Annual Meeting of the Endocrine Society, The Endocrine Society, San Diego, 2005.
32. N.N. Stone, V.P. Laudone, W.R. Fair, J. Fishman, Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions, Urol. Res. 15 (3) (1987) 165-167.
33. Y. Kaburagi, M.B. Marino, R.Y. Kirdani, J.P. Greco, J.P. Karr, A.A. Sandberg, The possibility of aromatization of androgen in human prostate, J. Steroid Biochem. 26 (6) (1987) 739-742.
34. H. Matzkin, M.S. Soloway, Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues, Prostate 21 (4) (1992) 309-314.
35. M. Tsugaya, N. Harada, K. Tozawa, Y. Yamada, Y. Hayashi, S. Tanaka, K. Maruyama, K. Kohri, Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer, Int. J. Urol. 3 (4) (1996) 292-296.
36. M. Hiramatsu, I. Maehara, M. Ozaki, N. Harada, S. Orikasa, H. Sasano, Aromatase in hyperplasia and carcinoma of the human prostate, Prostate 31 (1997) 118-124.
37. P. Negri-Cesi, A. Colciago, A. Poletti, M. Motta, 5alpha-Reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3, Prostate 41 (4) (1999) 224-232.
38. T. Smith, G.D. Chisholm, F.K. Habib, Failure of human benign prostatic hyperplasia to aromatise testosterone, J. Steroid Biochem. 17 (1) (1982) 119-120.
39. A.M. Brodie, C. Son, D.A. King, K.M. Meyer, S.E. Inkster, Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism, Cancer Res. 49 (23) (1989) 6551-6555.
40. P. Negri-Cesi, A. Poletti, A. Colciago, P. Magni, P. Martini, M. Motta, Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue, Prostate 34 (4) (1998) 283-291.
41. N. Harada, T. Utsumi, Y. Takagi, Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis, Proc. Natl. Acad. Sci. U.S.A. 90 (23) (1993) 11312-11316.
42. S.J. Ellem, J.F. Schmitt, J.S. Pedersen, M. Frydenberg, G.P. Risbridger, Local aromatase expression in human prostate is altered in malignancy, J. Clin. Endocrinol. Metab. 89 (5) (2004) 2434-2441.
43. G. Cunha, Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate, Cancer 74 (1994) 1030-1044.
44. L.D. Dikkeschei, B.G. Wolthers, I. Bos-Zuur, G.B. de la Riviere, G.T. Nagel, D.A. van der Kolk, P.H. Willemse, Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma, J. Steroid Biochem. Mol. Biol. 59 (3-4) (1996) 305-313.
45. E.R. Simpson, M.S. Mahendroo, J.E. Nichols, S.E. Bulun, Aromatase gene expression in adipose tissue: relationship to breast cancer, Int. J. Fertil. Menopausal Stud. 39 (Suppl 2) (1994) 75-83.
46. Y. Zhao, V.R. Agarwal, C.R. Mendelson, E.R. Simpson, Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene, Endocrinology 137 (12) (1996) 5739-5742.
47. E.R. Simpson, Y. Zhao, V.R. Agarwal, M.M. Dodson, S.E. Bulun, M.M. Hinshelwood, S. Graham-Lorence, T. Sun, C.R. Fisher, K. Qin, C.R. Mendelson, Aromatase expression in health and disease, Recent Prog. Horm. Res. 52 (1997) 185-214.
48. J.J. Bianco, S.J. McPherson, H. Wang, G.S. Prins, G.P. Risbridger, Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life, Am. J. Pathol. 168 (6) (2006) 1869-1878.
49. A.M.De Marzo, V.L. Marchi, J.I. Epstein, W.G. Nelson, Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis, Am. J. Pathol. 155 (6) (1999) 1985-1992.
50. W.G. Nelson, A.M. De Marzo, T.L. DeWeese, W.B. Isaacs, The role of inflammation in the pathogenesis of prostate cancer, J. Urol. 172 (5 Pt 2) (2004) S6-S11 (discussion S11-S12).
51. G.S. Palapattu, S. Sutcliffe, P.J. Bastian, E.A. Platz, A.M. De Marzo, W.B. Isaacs, W.G. Nelson, Prostate carcinogenesis and inflammation: emerging insights, Carcinogenesis 26 (7) (2005) 1170-1181.
52. G. Andrews, The histology of the human foetal and prepubertal prostates, J. Anat. 85 (1951) 44-54.
53. T. Zondek, L.H. Zondek, The fetal and neonatal prostate, in: M. Goland (Ed.), Normal and Abnormal Growth of the Prostate, Charles C Thomas, Springfield, IL, 1975.
54. W.E. Goodwin, R.H. Cummings, Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual, J. Urol. 131 (3) (1984) 553-554.
55. G. Risbridger, H. Wang, P. Young, T. Kurita, Y.Z. Wang, D. Lubahn, J.A. Gustafsson, G. Cunha, Y.Z. Wong, Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium, Dev. Biol. 229 (2) (2001) 432-442.
56. S.J. Ellem, H. Wang, M. Poutanen, G.P. Risbridger, Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy, Am. J. Pathol. 175 (3) (2009) 1187-1199.
57. B.M. Cattanach, C.A. Iddon, H.M. Charlton, S.A. Chiappa, G. Fink, Gonadotrophinreleasing hormone deficiency in a mutant mouse with hypogonadism, Nature 269 (5626) (1977) 338-340.
58. J.J. Bianco, D.J. Handelsman, J.S. Pedersen, G.P. Risbridger, Direct response of the murine prostate gland and seminal vesicles to estradiol, Endocrinology 143 (12) (2002) 4922-4933.
59. J.J. Bianco, S.J. McPherson, H. Wang, G.S. Prins, G.P. Risbridger, Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life, Am. J. Pathol. 168 (6) (2006) 1869-1878.
60. G.S. Prins, L. Birch, J.F. Couse, I. Choi, B. Katzenellenbogen, K.S. Korach, Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice, Cancer Res. 61 (16) (2001) 6089-6097.
61. W.A. Ricke, S.J. McPherson, J.J. Bianco, G.R. Cunha, Y. Wang, G.P. Risbridger, Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling, FASEB J. 22 (5) (2008) 1512-1520.
62. H. Bonkhoff, T. Fixemer, I. Hunsicker, K. Remberger, Estrogen receptor expression in prostate cancer and premalignant prostatic lesions, Am. J. Pathol. 155 (2) (1999) 641-647.
63. H. Bonkhoff, T. Fixemer, I. Hunsicker, K. Remberger, Progesterone receptor expression in human prostate cancer: correlation with tumor progression, Prostate 48 (4) (2001) 285-291.
64. P. Kastner, A. Krust, B. Turcotte, U. Stropp, L. Tora, H. Gronemeyer, P. Chambon, Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B, EMBO J. 9 (5) (1990) 1603-1614.
65. G.G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, J.A. Gustafsson, Cloning of a novel receptor expressed in rat prostate and ovary, Proc. Natl. Acad. Sci. U.S.A. 93 (12) (1996) 5925-5930.
66. C.H. Adlercreutz, B.R. Goldin, S.L. Gorbach, K.A. Hockerstedt, S. Watanabe, E.K. Hamalainen, M.H. Markkanen, T.H. Makela, K.T. Wahala, T. Adlercreutz, Soybean phytoestrogen intake and cancer risk, J. Nutr. 125 (3 Suppl.) (1995) 757S-770S.
67. H. Adlercreutz, Epidemiology of phytoestrogens, Baillieres Clin. Endocrinol. Metab. 12 (4) (1998) 605-623.
68. H. Adlercreutz, W. Mazur, P. Bartels, V. Elomaa, S. Watanabe, K. Wahala, M. Landstrom, E. Lundin, A. Bergh, J.E. Damber, P. Aman, A. Widmark, A. Johansson, J.X. Zhang, G. Hallmans, Phytoestrogens and prostate disease, J. Nutr. 130 (3) (2000) 658S-659S.
69. K. Griffiths, L. Denis, A. Turkes, M.S. Morton, Phytoestrogens and diseases of the prostate gland, Baillieres Clin. Endocrinol. Metab. 12 (4) (1998) 625-647.
70. S.J. McPherson, S.J. Ellem, V. Patchev, K.H. Fritzemeier, G.P. Risbridger, The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands, Ernst Schering Found. Symp. Proc. 1 (2006) 131-147.
71. S.J. McPherson, S.J. Ellem, E.R. Simpson, V. Patchev, K.H. Fritzemeier, G.P. Risbridger, Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia, Endocrinology 148 (2) (2007) 566-574.
72. Z. Weihua, S. Makela, L.C. Andersson, S. Salmi, S. Saji, J.I. Webster, E.V. Jensen, S. Nilsson, M. Warner, J.A. Gustafsson, A role for estrogen receptor beta in the regulation of growth of the ventral prostate, Proc. Natl. Acad. Sci. U.S.A. 98 (11) (2001) 6330-6335.
73. O. Imamov, A. Morani, G.J. Shim, Y. Omoto, C. Thulin-Andersson, M. Warner, J.A. Gustafsson, Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate, Proc. Natl. Acad. Sci. U.S.A. 101 (25) (2004) 9375-9380.
74. C.C. Chadwick, S. Chippari, E. Matelan, L. Borges-Marcucci, A.M. Eckert, J.C. Keith Jr., L.M. Albert, Y. Leathurby, H.A. Harris, R.A. Bhat, M. Ashwell, E. Trybulski, R.C. Winneker, S.J. Adelman, R.J. Steffan, D.C. Harnish, Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity, Proc. Natl. Acad. Sci. U.S.A. 102 (7) (2005) 2543-2548.
75. H.A. Harris, L.M. Albert, Y. Leathurby, M.S. Malamas, R.E. Mewshaw, C.P. Miller, Y.P. Kharode, J. Marzolf, B.S. Komm, R.C. Winneker, D.E. Frail, R.A. Henderson, Y. Zhu, J.C. Keith Jr., Evaluation of an estrogen receptor-beta agonist in animal models of human disease, Endocrinology 144 (10) (2003) 4241-4249.
76. G.S. Prins, K.S. Korach, The role of estrogens and estrogen receptors in normal prostate growth and disease, Steroids 73 (3) (2008) 233-244.
77. S. Savolainen, T. Pakarainen, I. Huhtaniemi, M. Poutanen, S. Makela, Delay of postnatal maturation sensitizes the mouse prostate to testosterone-induced pronounced hyperplasia: protective role of estrogen receptor-beta, Am. J. Pathol. 171 (3) (2007) 1013-1022.
78. L.G. Horvath, S.M. Henshall, C.S. Lee, D.R. Head, D.I. Quinn, S. Makela, W. Delprado, D. Golovsky, P.C. Brenner, G. O'Neill, R. Kooner, P.D. Stricker, J.J. Grygiel, J.A. Gustafsson, R.L. Sutherland, Frequent loss of estrogen receptor-beta expression in prostate cancer, Cancer Res. 61 (14) (2001) 5331-5335.
79. D. Pasquali, S. Staibano, D. Prezioso, R. Franco, D. Esposito, A. Notaro, G. De Rosa, A. Bellastella, A.A. Sinisi, Estrogen receptor beta expression in human prostate tissue, Mol. Cell Endocrinol. 178 (1-2) (2001) 47-50.
80. T. Fixemer, K. Remberger, H. Bonkhoff, Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma, Prostate 54 (2) (2003) 79-87.
81. O. Imamov, N.A. Lopatkin, J.A. Gustafsson, Estrogen receptor beta in prostate cancer, N. Engl. J. Med. 351 (26) (2004) 2773-2774.
82. G. Carruba, Estrogens and mechanisms of prostate cancer progression, Ann. NY Acad. Sci. 1089 (2006) 201-217.
83. G. Carruba, Estrogen and prostate cancer: an eclipsed truth in an androgendominated scenario, J. Cell Biochem. 102 (4) (2007) 899-911.
84. X. Zhu, I. Leav, Y.K. Leung, M. Wu, Q. Liu, Y. Gao, J.E. McNeal, S.M. Ho, Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis, Am. J. Pathol. 164 (6) (2004) 2003-2012.
85. D. Nojima, L.C. Li, A. Dharia, G. Perinchery, L. Ribeiro-Filho, T.S. Yen, R. Dahiya, CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma, Cancer 92 (8) (2001) 2076-2083.
86. S.M. Ho, W.Y. Tang, J. Belmonte de Frausto, G.S. Prins, Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4, Cancer Res. 66 (11) (2006) 5624-5632.
87. K.F. Koehler, L.A. Helguero, L.A. Haldosen, M. Warner, J.A. Gustafsson, Reflections on the discovery and significance of estrogen receptor beta, Endocr. Rev. 26 (3) (2005) 465-478.
88. W.A. Ricke, Y. Wang, G.R. Cunha, Steroid hormones and carcinogenesis of the prostate: the role of estrogens, Differentiation; Res. Biol. Diver. 75 (9) (2007) 871-882.
89. G.P. Risbridger, S.J. Ellem, S.J. McPherson, Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling, J. Mol. Endocrinol. 39 (3) (2007) 183-188.
90. S. Signoretti, M. Loda, Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am. J. Pathol. 159 (1) (2001) 13-16.
91. Y. Nakamura, T. Suzuki, T. Fukuda, A. Ito, M. Endo, T. Moriya, Y. Arai, H. Sasano, Steroid sulfatase and estrogen sulfotransferase in human prostate cancer, Prostate 66 (9) (2006) 1005-1012.
92. E. Koh, T. Noda, J. Kanaya, M. Namiki, Differential expression of 17betahydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues, Prostate 53 (2) (2002) 154-159.